Clinical Trial Update: Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial evaluating QL1706 plus lenvatinib as second-line therapy for metastatic esophageal squamous cell carcinoma after progression on ICIs; Phase 1/2, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• QL1706

Snippet

Sponsor: The First Affiliated Hospital of Zhengzhou University | Conditions: Esophageal Squamous Cell Carcinoma (ESCC) | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING